Improved asthma control with budesonide/formoterol via a single inhaler, compared with budesonide alone, in moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001
Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017
Is overall asthma control being achieved? A hypothesis-generating study Source: Eur Respir J 2001; 17: 589-595 Year: 2001
Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 43s Year: 2001
Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial Source: Eur Respir J 2007; 30: 457-466 Year: 2007
Once per day inhaled corticosteroids: a method to improve compliance and asthma control Source: Eur Respir J 2001; 18: Suppl. 33, 441s Year: 2001
Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone Source: Eur Respir J 2001; 18: 262-268 Year: 2001
Children with mild asthma: do they benefit from inhaled corticosteroids? Source: Eur Respir J 2002; 20: 1470-1475 Year: 2002
Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function Source: Eur Respir J 2008; 32: 989-996 Year: 2008
Utility of high dose inhaled fluticasone therapy for the early management of acute exacerbations of asthma Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
Achieving guideline-based asthma control: does the patient benefit? Source: Eur Respir J 2002; 20: 588-596 Year: 2002
Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
The concept study: comparative influence of two treatment strategies on airway response to AMP Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how? Year: 2005
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Budesonide and formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroid in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 159s Year: 2001
Low dose inhaled budesonide with and without formoterol in steroid free patients with mild persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001
Comparative study of 8-weeks treatment of asthma exacerbations in adults with high doses of budesonide versus fluticasone Source: Eur Respir J 2001; 18: Suppl. 33, 97s Year: 2001